Cerus Corporation (CERS)
NASDAQ: CERSHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CERS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $373.62M
- Forward P/E
- 123.33
- EPS (TTM)
- -$0.04
- Dividend yield
- None
- 52-week range
- 1.59 – 3.47
- Day range
- 1.82 – 1.95
- Volume / Avg
- 4.51M / 2.12M
- Beta
- —
- Shares outstanding
- 201.95M
52-week range
CERS stock today
On Nov 20, CERS ended the session at $1.85, shedding $0.05 (2.63%), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 4.51M shares, a sign of unusually heavy trading. Shares are 46.7% below their 52-week high of $3.47, set on Jul 6, 2026 and 16.4% above the 52-week low of $1.59, near the bottom of the past year's range.
CERS is down 10.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.2%. Cerus has posted a net loss over the last twelve months (EPS of -$0.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cerus
Company profileCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Vivek K. Jayaraman
- Headquarters
- Concord, CA
- Employees
- 261
- IPO year
- 1997
- Website
- cerus.com
Financial highlights
Full financialsIn fiscal 2025, Cerus generated $233.8 million in revenue, up 16.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Cerus reported a net loss of $15.6 million, compared with a loss of $20.9 million a year earlier. Operating margin was -3.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $233.80M | $201.32M | $186.80M | $188.31M | $159.52M |
| Growth | +16.13% | +7.78% | -0.81% | +18.05% | +39.62% |
| Net income | $-15.63M | $-20.92M | $-37.49M | $-42.78M | $-54.37M |
| EPS (diluted) | $-0.08 | $-0.11 | $-0.21 | $-0.24 | $-0.32 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$5.13+177.30%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $0.00 vs $-0.01
- Surprise
- +100.00%
CERS news
All CERS newsCerus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MOBIMobia Medical Inc. | 11.85 | -0.08% | $394.50M | vs CERS |
| BWAYBrainsWay Ltd. ADR | 8.48 | -2.86% | $341.35M | vs CERS |
| EMBCEmbecta Corp. | 6.02 | -2.75% | $341.09M | vs CERS |
| SIShoulder Innovations Inc. | 20.15 | -0.79% | $421.58M | vs CERS |
| SENSSenseonics Holdings Inc. | 8.02 | -9.94% | $439.34M | vs CERS |
| MDXGMiMedx Group Inc | 3.05 | -1.93% | $445.07M | vs CERS |
| ANGOAngioDynamics Inc. | 10.81 | +0.46% | $454.61M | vs CERS |
| INFUInfuSystems Holdings Inc. | 14.35 | +2.06% | $287.48M | vs CERS |
Indexes, lists and sector
Cerus stock FAQ
What is Cerus's stock price today?
CERS last traded at $1.85 as of Nov 20, 4:00 PM EST, down 2.63% on the day. Prices are delayed at least 15 minutes.
Who is Cerus's CEO?
Mr. Vivek K. Jayaraman is the chief executive officer of Cerus Corporation, which has about 261 employees.
What is the CERS 52-week high?
The 52-week high for CERS is $3.47 and the 52-week low is $1.59. The stock is currently 46.7% below its high.